Ultrasonography-guided radiofrequency ablation for the treatment of T2N0M0 papillary thyroid carcinoma: a preliminary study
Purpose To evaluate the efficacy and safety of ultrasonography (US)-guided radiofrequency ablation (RFA) for treating T2N0M0 papillary thyroid cancer (PTC). Methods This retrospective study was approved by the ethics committee of Chinese PLA General Hospital (S2019-211-01). Twelve patients with T2N0...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-01-01
|
| Series: | International Journal of Hyperthermia |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/02656736.2021.1895332 |
| _version_ | 1818967608975687680 |
|---|---|
| author | Jing Xiao Yan Zhang Mingbo Zhang Fang Xie Lin Yan Yukun Luo Jie Tang |
| author_facet | Jing Xiao Yan Zhang Mingbo Zhang Fang Xie Lin Yan Yukun Luo Jie Tang |
| author_sort | Jing Xiao |
| collection | DOAJ |
| description | Purpose To evaluate the efficacy and safety of ultrasonography (US)-guided radiofrequency ablation (RFA) for treating T2N0M0 papillary thyroid cancer (PTC). Methods This retrospective study was approved by the ethics committee of Chinese PLA General Hospital (S2019-211-01). Twelve patients with T2N0M0 PTC (five men and seven women with a mean age of 41.0 ± 9.2 years (range, 21–61 years)), who were not eligible for or refused surgery, were included in our study. RFA was performed with the moving-shot technique, and the ablation area exceeded the tumor edge by at least 3 mm. US was performed before RFA, immediately, 1, 3 , 6 and 12 months after RFA, and every 6–12 months thereafter. Results All tumors were ablated as planned. The mean follow-up duration was 24.1 ± 6.9 months (range, 13–33 months). The tumor volume decreased significantly from 4.4 ± 2.8 ml to 0.3 ± 0.5 ml, and the volume reduction rate (VRR) was (93.7 ± 7.6)% at the final follow-up with two tumors (16.7%) disappearing. New or recurrent tumors were not found, and no local or distant metastasis were detected during follow-up. No life-threatening or delayed complications were observed. Conclusion RFA may be a potential alternative to surgery for the management of T2N0M0 PTC in select patients, especially for those who are ineligible for surgery. |
| first_indexed | 2024-12-20T13:51:31Z |
| format | Article |
| id | doaj.art-c1fbdf1ac91f433392e1b540781a4dff |
| institution | Directory Open Access Journal |
| issn | 0265-6736 1464-5157 |
| language | English |
| last_indexed | 2024-12-20T13:51:31Z |
| publishDate | 2021-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | International Journal of Hyperthermia |
| spelling | doaj.art-c1fbdf1ac91f433392e1b540781a4dff2022-12-21T19:38:30ZengTaylor & Francis GroupInternational Journal of Hyperthermia0265-67361464-51572021-01-0138140240810.1080/02656736.2021.18953321895332Ultrasonography-guided radiofrequency ablation for the treatment of T2N0M0 papillary thyroid carcinoma: a preliminary studyJing Xiao0Yan Zhang1Mingbo Zhang2Fang Xie3Lin Yan4Yukun Luo5Jie Tang6Department of Ultrasound, The First Medical Center of Chinese PLA General HospitalDepartment of Ultrasound, The First Medical Center of Chinese PLA General HospitalDepartment of Ultrasound, The First Medical Center of Chinese PLA General HospitalDepartment of Ultrasound, The First Medical Center of Chinese PLA General HospitalDepartment of Ultrasound, The First Medical Center of Chinese PLA General HospitalDepartment of Ultrasound, The First Medical Center of Chinese PLA General HospitalDepartment of Ultrasound, The First Medical Center of Chinese PLA General HospitalPurpose To evaluate the efficacy and safety of ultrasonography (US)-guided radiofrequency ablation (RFA) for treating T2N0M0 papillary thyroid cancer (PTC). Methods This retrospective study was approved by the ethics committee of Chinese PLA General Hospital (S2019-211-01). Twelve patients with T2N0M0 PTC (five men and seven women with a mean age of 41.0 ± 9.2 years (range, 21–61 years)), who were not eligible for or refused surgery, were included in our study. RFA was performed with the moving-shot technique, and the ablation area exceeded the tumor edge by at least 3 mm. US was performed before RFA, immediately, 1, 3 , 6 and 12 months after RFA, and every 6–12 months thereafter. Results All tumors were ablated as planned. The mean follow-up duration was 24.1 ± 6.9 months (range, 13–33 months). The tumor volume decreased significantly from 4.4 ± 2.8 ml to 0.3 ± 0.5 ml, and the volume reduction rate (VRR) was (93.7 ± 7.6)% at the final follow-up with two tumors (16.7%) disappearing. New or recurrent tumors were not found, and no local or distant metastasis were detected during follow-up. No life-threatening or delayed complications were observed. Conclusion RFA may be a potential alternative to surgery for the management of T2N0M0 PTC in select patients, especially for those who are ineligible for surgery.http://dx.doi.org/10.1080/02656736.2021.1895332thyroidpapillary carcinomaradiofrequencythermal ablationultrasonographyvolume reduction rate |
| spellingShingle | Jing Xiao Yan Zhang Mingbo Zhang Fang Xie Lin Yan Yukun Luo Jie Tang Ultrasonography-guided radiofrequency ablation for the treatment of T2N0M0 papillary thyroid carcinoma: a preliminary study International Journal of Hyperthermia thyroid papillary carcinoma radiofrequency thermal ablation ultrasonography volume reduction rate |
| title | Ultrasonography-guided radiofrequency ablation for the treatment of T2N0M0 papillary thyroid carcinoma: a preliminary study |
| title_full | Ultrasonography-guided radiofrequency ablation for the treatment of T2N0M0 papillary thyroid carcinoma: a preliminary study |
| title_fullStr | Ultrasonography-guided radiofrequency ablation for the treatment of T2N0M0 papillary thyroid carcinoma: a preliminary study |
| title_full_unstemmed | Ultrasonography-guided radiofrequency ablation for the treatment of T2N0M0 papillary thyroid carcinoma: a preliminary study |
| title_short | Ultrasonography-guided radiofrequency ablation for the treatment of T2N0M0 papillary thyroid carcinoma: a preliminary study |
| title_sort | ultrasonography guided radiofrequency ablation for the treatment of t2n0m0 papillary thyroid carcinoma a preliminary study |
| topic | thyroid papillary carcinoma radiofrequency thermal ablation ultrasonography volume reduction rate |
| url | http://dx.doi.org/10.1080/02656736.2021.1895332 |
| work_keys_str_mv | AT jingxiao ultrasonographyguidedradiofrequencyablationforthetreatmentoft2n0m0papillarythyroidcarcinomaapreliminarystudy AT yanzhang ultrasonographyguidedradiofrequencyablationforthetreatmentoft2n0m0papillarythyroidcarcinomaapreliminarystudy AT mingbozhang ultrasonographyguidedradiofrequencyablationforthetreatmentoft2n0m0papillarythyroidcarcinomaapreliminarystudy AT fangxie ultrasonographyguidedradiofrequencyablationforthetreatmentoft2n0m0papillarythyroidcarcinomaapreliminarystudy AT linyan ultrasonographyguidedradiofrequencyablationforthetreatmentoft2n0m0papillarythyroidcarcinomaapreliminarystudy AT yukunluo ultrasonographyguidedradiofrequencyablationforthetreatmentoft2n0m0papillarythyroidcarcinomaapreliminarystudy AT jietang ultrasonographyguidedradiofrequencyablationforthetreatmentoft2n0m0papillarythyroidcarcinomaapreliminarystudy |